The efficacy and safety of 12-week SOF/VEL regimen combined with prophylactic use of TAF for treatment-nave genotype 1-6 HCV/HBV co-infection adult patients with or without compensated cirrhosis in China: a mutil-center, prospective, single-arm, open-label trial
Latest Information Update: 03 Aug 2020
Price :
$35 *
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary) ; Tenofovir alafenamide (Primary)
- Indications Hepatitis B; Hepatitis C
- Focus Therapeutic Use
- 03 Aug 2020 New trial record